menu
    • menu
    [{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Fasinumab","moa":"Beta-nerve growth factor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Fasinumab","moa":"Beta-nerve growth factor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Fasinumab","moa":"Beta-nerve growth factor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Fasinumab","moa":"Beta-nerve growth factor","graph1":"Neurology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Fasinumab","moa":"Beta-nerve growth factor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Fasinumab","moa":"Beta-nerve growth factor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Fasinumab","moa":"Beta-nerve growth factor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Fasinumab","moa":"Beta-nerve growth factor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Fasinumab","moa":"Beta-nerve growth factor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Teva Pharmaceutical Industries"}]

    Find Clinical Drug Pipeline Developments & Deals for Fasinumab

    Menu

    Fasinumab

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Regeneron Pharmaceuticals

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Regeneron Pharmaceuticals

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fasinumab,Naproxen,Diclofenac,Celecoxib

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip

                            Details : Fasinumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Osteoarthritis, Knee.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            May 14, 2019

                            Lead Product(s) : Fasinumab,Naproxen,Diclofenac,Celecoxib

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Regeneron Pharmaceuticals

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Regeneron Pharmaceuticals

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fasinumab

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarth...

                            Details : Fasinumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Osteoarthritis, Knee.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            October 02, 2018

                            Lead Product(s) : Fasinumab

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Regeneron Pharmaceuticals

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Regeneron Pharmaceuticals

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fasinumab

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            To Assess the Patients' Ability to Self-Administer Fasinumab

                            Details : Fasinumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Osteoarthritis, Knee.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 09, 2018

                            Lead Product(s) : Fasinumab

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Regeneron Pharmaceuticals

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Regeneron Pharmaceuticals

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fasinumab

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflamma...

                            Details : Fasinumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoarthritis, Knee.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            October 09, 2017

                            Lead Product(s) : Fasinumab

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Regeneron Pharmaceuticals

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Regeneron Pharmaceuticals

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fasinumab

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Os...

                            Details : Fasinumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Back Pain.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 18, 2017

                            Lead Product(s) : Fasinumab

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Regeneron Pharmaceuticals

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Regeneron Pharmaceuticals

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fasinumab

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment o...

                            Details : Fasinumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoarthritis, Knee.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            May 19, 2017

                            Lead Product(s) : Fasinumab

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Regeneron Pharmaceuticals

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Regeneron Pharmaceuticals

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fasinumab

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee ...

                            Details : Fasinumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoarthritis, Knee.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            February 17, 2016

                            Lead Product(s) : Fasinumab

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Regeneron Pharmaceuticals

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Regeneron Pharmaceuticals

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fasinumab

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pa...

                            Details : Fasinumab is a Antibody drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Low Back Pain.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            December 02, 2015

                            Lead Product(s) : Fasinumab

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Regeneron Pharmaceuticals

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Regeneron Pharmaceuticals

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fasinumab

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects

                            Details : Fasinumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 06, 2015

                            Lead Product(s) : Fasinumab

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.